Corvus Pharmaceuticals, Inc.

For the period ended Sep 30, 2025. Filed Nov 4, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 4, 2025

CRVS$11.37+0.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Change in Stockholders’ Equity

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(in thousands, except share data)


· · Nine Months Ended September 30, 2025
· · · · · · · Accumulated · · · ·
· · · · · · · Additional · · Other · · · · · Total
· · Common Stock · · Paid-in · · Comprehensive · · Accumulated · · Stockholders’
· Shares · Amount · Capital · Loss · Deficit · Equity
Balance at December 31, 2024	67,899,779	$7	$430,859	$(1,288)	$(397,010)	$32,568
Common stock issued upon exercise of stock options	269,682	—	279	—	—	279
Stock-based compensation expense	—	—	1,251	—	—	1,251
Unrealized loss on marketable securities	—	—	—	(23)	—	(23)
Foreign currency translation adjustment	—	—	—	57	—	57
Net income	—	—	—	—	15,193	15,193
Balance at March 31, 2025	68,169,461	$7	$432,389	$(1,254)	$(381,817)	$49,325
Issuance of common stock upon exercise of common stock warrants	6,330,578	—	23,053	—	—	23,053
Issuance of pre-funded warrants upon exercise of common stock warrants	—	—	14,461	—	—	14,461
Common stock issued upon exercise of stock options	14,000	—	25	—	—	25
Stock-based compensation expense	—	—	1,256	—	—	1,256
Unrealized loss on marketable securities	—	—	—	(19)	—	(19)
Foreign currency translation adjustment	—	—	—	125	—	125
Net loss	—	—	—	—	(7,998)	(7,998)
Balance at June 30, 2025	74,514,039	$7	$471,184	$(1,148)	$(389,815)	$80,228
Common stock issued on exercise of stock options	167,833	—	360	—	—	360
Stock-based compensation expense	—	—	1,249	—	—	1,249
Unrealized gain on marketable securities	—	—	—	29	—	29
Foreign currency translation adjustment	—	—	—	59	—	59
Net loss	—	—	—	—	(10,157)	(10,157)
Balance at September 30, 2025	74,681,872	$7	$472,793	$(1,060)	$(399,972)	$71,768


· · Nine Months Ended September 30, 2024
· · · · · · · Accumulated · · · ·
· · · · · · · Additional · · Other · · · · · Total
· · Common Stock · · Paid-in · · Comprehensive · · Accumulated · · Stockholders’
· Shares · Amount · Capital · Loss · Deficit · Equity
Balance at December 31, 2023	49,038,582	$5	$374,363	$(967)	$(334,717)	$38,684
Stock-based compensation expense	—	—	689	—	—	689
Unrealized loss on marketable securities	—	—	—	(15)	—	(15)
Foreign currency translation adjustment	—	—	—	(293)	—	(293)
Net loss	—	—	—	—	(5,701)	(5,701)
Balance at March 31, 2024	49,038,582	$5	$375,052	$(1,275)	$(340,418)	$33,364
Common stock issued in connection with registered direct offering, net	13,512,699	1	16,404	—	—	16,405
Pre-funded warrants issued in connection with registered direct offering, net	—	—	5,031	—	—	5,031
Stock-based compensation expense	—	—	768	—	—	768
Unrealized gain on marketable securities	—	—	—	5	—	5
Foreign currency translation adjustment	—	—	—	(85)	—	(85)
Net loss	—	—	—	—	(4,262)	(4,262)
Balance at June 30, 2024	62,551,281	$6	$397,255	$(1,355)	$(344,680)	$51,226
Common stock issued on exercise of stock options	28,750	—	50	—	—	50
Stock-based compensation expense	—	—	733	—	—	733
Unrealized gain on marketable securities	—	—	—	152	—	152
Foreign currency translation adjustment	—	—	—	465	—	465
Net loss	—	—	—	—	(40,217)	(40,217)
Balance at September 30, 2024	62,580,031	$6	$398,038	$(738)	$(384,897)	$12,409

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.